Crown Electrokinetics Corp.: Nasdaq/NYSE listing notice — Crown Electrokinetics Receives Nasdaq Delisting Notice for Low Priced Stock; Plans Appeal

Crown Electrokinetics Corp.

Nasdaq notified Crown on March 4 that its stock closed below $0.10 for 10 consecutive trading days through March 1, triggering Listing Rule 5810(c)(3)(A)(iii) delisting.
Company previously failed $1.00 bid price rule (Oct 2023) and has until April 16, 2024 to regain compliance.
Crown plans to timely request a hearing before the Nasdaq Hearings Panel to stay delisting; no guarantee of relief.
Common stock continues trading on Nasdaq under symbol CRKN during the hearing process.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Crown Electrokinetics Corp. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii), 5550(a)(2)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5810(c)(3)(A)(iii), 5550(a)(2)

Exact text from the filing

March 4, 2024, the Company received another letter from the Staff (the “March Notice”) notifying the Company that the bid price for the Company’s common stock had closed below $0.10 for the 10-consecutive trading day period ended March 1, 2024 and, accordingly, the Company is subject to the provisions contemplated under Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stock Rule”). As a result, the Staff indicated that the Company’s securities would be delisted from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to t

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001213900-24-021074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.